CccDNA

Last updated

cccDNA (covalently closed circular DNA) is a special DNA structure that arises during the propagation of some viruses in the cell nucleus and may remain permanently there. It is a double-stranded DNA that originates in a linear form that is ligated by means of DNA ligase to a covalently closed ring. In most cases, transcription of viral DNA can occur from the circular form only. The cccDNA of viruses is also known as episomal DNA or occasionally as a minichromosome.

Contents

cccDNA was first described in bacteriophages, but it was also found in some cell cultures where an infection of DNA viruses ( Polyomaviridae ) was detected. [1] [2] cccDNA is typical of Caulimoviridae and Hepadnaviridae , including the hepatitis B virus (HBV). cccDNA in HBV is formed by conversion of capsid-associated relaxed circular DNA (rcDNA). [3] Following hepatitis B infections, cccDNA can remain following clinical treatment in liver cells and can rarely reactivate. The relative quantity of cccDNA present is an indicator for HBV treatment. [4]

Background of cccDNA and the Hepatitis B virus

Closed covalent circular DNA (cccDNA) is a unique DNA structure that forms in response to infection of a cell. Genomic DNA enters the cell nucleus, and partially double-stranded DNA is then converted into cccDNA.

CccDNA is primarily seen in the context of the Hepatitis B virus (HBV).  Approximately 257 million people worldwide are chronically infected with the virus, placing them at high risk for developing cirrhosis and hepatocellular carcinoma (HCC). [5]   Chronic infection is characterized by the persistence of the cccDNA minichromosome in the nuclei of host hepatocytes (liver cells). [6]   Current treatments are unable to completely clear the viral minichromosome from the host hepatocytes, [7] and as a result aim to “functionally cure” the host, which requires a blockade of the viral cccDNA through transcriptional silencing. [5]   The infected individual cannot be completely cured without a clearance of cccDNA from infected hepatocytes, which at present is not possible. [8]

CDC Recommended Vaccine Schedule 0-18yrs-child-combined-schedule.pdf
CDC Recommended Vaccine Schedule

The HBV pathogen is a small, blood-transmitted virus with high tissue and species specificity that is transmitted through exposure to infected blood or bodily fluids. [6]   The only cells that the virus can infect are hepatocytes, and these are reached by means of the bloodstream after infection. [6]   Hepatocytes are cells from liver tissue that are involved in protein synthesis and storage. While this disease can be prevented by vaccination, high-risk individuals such as infants can have as high as a 90% chance of chronic liver disease if not previously vaccinated. [9]   As a result, the CDC recommends the first dose of hepatitis B vaccine be administered immediately at birth. [10]   CccDNA and its persistence in the nucleus remains the main obstacle for an effective cure and is therefore the reason for the rigorous hepatitis B vaccination schedule. [10]

In practice, the only known organism that makes use of cccDNA is the Hepatitis B Virus. More specifically, cccDNA is a reactive intermediate that significantly contributes to infections of hepatocytes. [11] The persistence of cccDNA throughout the duration of the infection has been a key player in the prevalence of HBV. [11] Research indicates that cccDNA is actually the primary reason that historically, there has been little progress toward eradicating HBV. [12] In many cases, even after the infection has been resolved, cccDNA can still be detected. [12] Currently, therapy for HBV involves nucleotide analogues (NAs), which initially were implemented in clinical use in the late 1990s.[ citation needed ] Though many different therapeutic techniques have been trialed over the years, a cure for HBV has yet to be discovered. Researchers attribute this to the continued inability to disable the cccDNA.[ citation needed ] Future therapies will need to focus directly on eliminating this factor.

Properties of cccDNA

A generic half life graph which can be used to model cccDNA half life using the time of half life for cccDNA. A generic half life graph.jpg
A generic half life graph which can be used to model cccDNA half life using the time of half life for cccDNA.

CccDNA is able to form a stable minichromosome in the nucleus of cells that are infected with a particular virus associated with cccDNA. [13] As part of the nucleus, cccDNA is able to interact with histone and non-histone proteins to form structures similar to chromatin. [14] In the same way as host chromatin, cccDNA transcription is regulated through the control of two enhancers and four distinct promoters. It also depends on multiple regulators including transcription factors, co-activators, co-repressors and chromatin modifying enzymes. In addition, cccDNA can serve as a template for viral replication and DNA transcription for five viral RNAs which allows for the production of the viral antigens. [13]

It is challenging to quantify the number of copies of cccDNA in each cell as it depends on the type of cell and the type of infection. Although the half life of cccDNA has not been determined yet, it has been tested in vitro to last during the lifespan of the cell. [13] In a recent in vitro study on HBV, the results showed that the half life of the human liver cell (HepG2) is 40 days and provides an estimated lifespan of 58 days. The half life in vivo of human liver cells has not yet been determined. [15]

Role of cccDNA in HBV replication

CccDNA is associated with the hepatitis B virus (HBV), where the virus constructs its plasmid through covalently linking its bonds. The histone-containing region of the nucleus within the virus is where cccDNA is commonly found, usually interacting with the histones similar to that of chromatin. The models available for determining bacterial specificity is currently limited to three cell culture types: primary tupaia, or human hepatocytes (PHH), and differentiated HepaRG (dHepaRG). [16] It is from these models that HBV replication was observed via transcription of the cccDNA. It is these lack of models that prevent drug treatment, due to the lack of efficiency in eradicating the cccDNA. [17]

HepaRG was the first cell line to successfully support HBV infection, and demonstrated that the infection can only be hosted by human hepatocytes. [18] Once hepatocyte-like cells were exposed to differentiation inducers, the viral source was introduced from a known HBV carrier containing high levels of cccDNA, and the HBV surface antigen levels were analyzed, indicating that the infection had successfully been replicated in HepaRG cells. [19] Typically HBV is measured by the cccDNA levels via Southern blot kinetics of healthy vs infected cells and quantified by dot blot. In these infected cells, there is a strong correlation between the cccDNA, that acts as a replication marker, and secretion levels of the surface antigen, HBsAg. [18]

Biological functions

CccDNA is formed from rcDNA (relaxed circular DNA) through the removal of a viral polymerase on the 5’ end of the negative strand of DNA, the removal of the 5’ end of the plus strand, and the removal of one copy of the short terminal redundancy from the minus strand. After these removals occur, the positive strand is completed and ligation of the two viral DNA strands occurs. [16] The mechanism of infection stems from the conversion of relaxed circular double stranded DNA (rcDNA) into cccDNA, from virus templates, speculated to be performed by the cell's own DNA repair enzymes. This process occurs due to the retrotranscription of a cccDNA transcript into the normal cell's rcDNA genomes. Deprotonation of the rcDNA then acts as a precursor of cccDNA via a polymerase chain reaction. [20] [21] While there is debate concerning the next steps in the mechanisms for formation and metabolism of cccDNA, it is known that ligase inhibitors play a crucial role as knockout experiments support. DNA ligase 1 and DNA ligase 3 directly reduce the formation of cccDNA, whereas DNA ligase 4 is crucial for cccDNA formation in only the double stranded linear DNA. [21]

This conversion of partially double stranded rcDNA into cccDNA generally occurs when a hepatocyte becomes infected. [22] cccDNA can produce all of the equipment necessary to complete viral replication and protein production and therefore does not need to use its host's semi-conservative DNA replication machinery. [22]

Triggers and controls of cccDNA production are not fully known, but it is thought that there may be a system involving negative feedback to suppress cccDNA production once about 10-50 copies are made. cccDNA pools, once made, are easily maintained so it is not necessary for a cell to be infected multiple times to create a cccDNA pool. [23] cccDNA can be diluted and or lost through mitosis, but in general cccDNA can exist over the course of a hepatocyte's lifecycle without impacting its viability. This lifelong persistence of cccDNA is hypothesized to explain observed lifelong immune responses to HBV. [24]

Immune mediated, epigenetic, and viral factors are all thought to have an impact on cccDNA activity. Investigation into the mechanisms through which these various factors influence cccDNA activity in vivo is rather limited due to the select animal hosts that are available. [25] In regards to immune mediated factors, research has shown that inflammatory cytokines can suppress viral replication and diminish cccDNA pools in infected cells. Additionally, acetylation and deacetylation of cccDNA is thought to regulate transcription of cccDNA and thus its viral replication. Acetylation has been found to correlate with viral replication while deacetylation has been found to be correlated with low viral replication in vitro. [22] Further investigation is needed to study the effects of acetylation and deacetylation on cccDNA activity in vivo.

Related Research Articles

<span class="mw-page-title-main">Hepatitis</span> Inflammation of the liver

Hepatitis is inflammation of the liver tissue. Some people or animals with hepatitis have no symptoms, whereas others develop yellow discoloration of the skin and whites of the eyes (jaundice), poor appetite, vomiting, tiredness, abdominal pain, and diarrhea. Hepatitis is acute if it resolves within six months, and chronic if it lasts longer than six months. Acute hepatitis can resolve on its own, progress to chronic hepatitis, or (rarely) result in acute liver failure. Chronic hepatitis may progress to scarring of the liver (cirrhosis), liver failure, and liver cancer.

Hepatitis D is a type of viral hepatitis caused by the hepatitis delta virus (HDV). HDV is one of five known hepatitis viruses: A, B, C, D, and E. HDV is considered to be a satellite because it can propagate only in the presence of the hepatitis B virus (HBV). Transmission of HDV can occur either via simultaneous infection with HBV (coinfection) or superimposed on chronic hepatitis B or hepatitis B carrier state (superinfection).

<i>Hepadnaviridae</i> Family of viruses

Hepadnaviridae is a family of viruses. Humans, apes, and birds serve as natural hosts. There are currently 18 species in this family, divided among 5 genera. Its best-known member is hepatitis B virus. Diseases associated with this family include: liver infections, such as hepatitis, hepatocellular carcinomas, and cirrhosis. It is the sole accepted family in the order Blubervirales.

<span class="mw-page-title-main">Viral hepatitis</span> Liver inflammation from a viral infection

Viral hepatitis is liver inflammation due to a viral infection. It may present in acute form as a recent infection with relatively rapid onset, or in chronic form, typically progressing from a long-lasting asymptomatic condition up to a decompensated hepatic disease and hepatocellular carcinoma (HCC).

<span class="mw-page-title-main">Satellite (biology)</span> Subviral agent which depends on a helper virus for its replication

A satellite is a subviral agent that depends on the coinfection of a host cell with a helper virus for its replication. Satellites can be divided into two major classes: satellite viruses and satellite nucleic acids. Satellite viruses, which are most commonly associated with plants, are also found in mammals, arthropods, and bacteria. They encode structural proteins to enclose their genetic material, which are therefore distinct from the structural proteins of their helper viruses. Satellite nucleic acids, in contrast, do not encode their own structural proteins, but instead are encapsulated by proteins encoded by their helper viruses. The genomes of satellites range upward from 359 nucleotides in length for satellite tobacco ringspot virus RNA (STobRV).

<span class="mw-page-title-main">Oncovirus</span> Viruses that can cause cancer

An oncovirus or oncogenic virus is a virus that can cause cancer. This term originated from studies of acutely transforming retroviruses in the 1950–60s, when the term "oncornaviruses" was used to denote their RNA virus origin. With the letters "RNA" removed, it now refers to any virus with a DNA or RNA genome causing cancer and is synonymous with "tumor virus" or "cancer virus". The vast majority of human and animal viruses do not cause cancer, probably because of longstanding co-evolution between the virus and its host. Oncoviruses have been important not only in epidemiology, but also in investigations of cell cycle control mechanisms such as the retinoblastoma protein.

<span class="mw-page-title-main">Entecavir</span> Chemical compound

Entecavir (ETV), sold under the brand name Baraclude, is an antiviral medication used in the treatment of hepatitis B virus (HBV) infection. In those with both HIV/AIDS and HBV antiretroviral medication should also be used. Entecavir is taken by mouth as a tablet or solution.

<span class="mw-page-title-main">Hepatitis B</span> Human viral infection

Hepatitis B is an infectious disease caused by the Hepatitis B virus (HBV) that affects the liver; it is a type of viral hepatitis. It can cause both acute and chronic infection.

<span class="mw-page-title-main">HBx</span>

HBx is a hepatitis B viral protein. It is 154 amino acids long and interferes with transcription, signal transduction, cell cycle progress, protein degradation, apoptosis and chromosomal stability in the host. It forms a heterodimeric complex with its cellular target protein, and this interaction dysregulates centrosome dynamics and mitotic spindle formation. It interacts with DDB1 redirecting the ubiquitin ligase activity of the CUL4-DDB1 E3 complexes, which are intimately involved in the intracellular regulation of DNA replication and repair, transcription and signal transduction.

<span class="mw-page-title-main">HBcAg</span>

HBcAg is a hepatitis B viral protein. It is an indicator of active viral replication; this means the person infected with Hepatitis B can likely transmit the virus on to another person.

<span class="mw-page-title-main">HBeAg</span> Hepatitis B viral protein

HBeAg is a hepatitis B viral protein, produced by the HBcAg reading frame. It is an indicator of active viral replication; this means the person infected with Hepatitis B can likely transmit the virus on to another person. HBeAg is considered a marker for cccDNA replication.

<span class="mw-page-title-main">Hepatitis B virus DNA polymerase</span>

Hepatitis B virus DNA polymerase is a hepatitis B viral protein. It is a DNA polymerase that can use either DNA or RNA templates and a ribonuclease H that cuts RNA in the duplex. Both functions are supplied by the reverse transcriptase (RT) domain.

<i>Hepatitis B virus</i> Species of the genus Orthohepadnavirus

Hepatitis B virus (HBV) is a partially double-stranded DNA virus, a species of the genus Orthohepadnavirus and a member of the Hepadnaviridae family of viruses. This virus causes the disease hepatitis B.

The transmission of hepadnaviruses between their natural hosts, humans, non-human primates, and birds, including intra-species host transmission and cross-species transmission, is a topic of study in virology.

<span class="mw-page-title-main">Sharon Lewin</span> Australian infectious disease physician and researcher

Sharon Ruth Lewin, FRACP, FAHMS is an Australian physician who is the inaugural Director of The Peter Doherty Institute for Infection and Immunity. She is also a Professor of Medicine at The University of Melbourne, a National Health and Medical Research Council (NHMRC) Practitioner Fellow, Director of the Cumming Global Centre for Pandemic Therapeutics, and President of the International AIDS Society (IAS).

<i>Ground squirrel hepatitis virus</i> Species of virus

Ground squirrel hepatitis virus, abbreviated GSHV, is a partially double-stranded DNA virus that is closely related to human Hepatitis B virus (HBV) and Woodchuck hepatitis virus (WHV). It is a member of the family of viruses Hepadnaviridae and the genus Orthohepadnavirus. Like the other members of its family, GSHV has high degree of species and tissue specificity. It was discovered in Beechey ground squirrels, Spermophilus beecheyi, but also infects Arctic ground squirrels, Spermophilus parryi. Commonalities between GSHV and HBV include morphology, DNA polymerase activity in genome repair, cross-reacting viral antigens, and the resulting persistent infection with viral antigen in the blood (antigenemia). As a result, GSHV is used as an experimental model for HBV.

<i>Woolly monkey hepatitis B virus</i> Species of virus

The woolly monkey hepatitis B virus (WMHBV) is a viral species of the Orthohepadnavirus genus of the Hepadnaviridae family. Its natural host is the woolly monkey (Lagothrix), an inhabitant of South America categorized as a New World primate. WMHBV, like other hepatitis viruses, infects the hepatocytes, or liver cells, of its host organism. It can cause hepatitis, liver necrosis, cirrhosis, and hepatocellular carcinoma. Because nearly all species of Lagothrix are threatened or endangered, researching and developing a vaccine and/or treatment for WMHBV is important for the protection of the whole woolly monkey genus.

Francis "Frank" Vincent Chisari is a physician, experimental pathologist, virologist, and immunologist, known for his research on virus-host interactions of hepatitis B and hepatitis C.

<span class="mw-page-title-main">HepaRG</span> Hepatic cell line model

HepaRG cell line is a human hepatic in vitro line used in liver biology research and for assessing liver pathology, hepatotoxicity, and drug-induced injury. The HepaRG model is considered a surrogate for Primary Human Hepatocytes, which are the most pertinent model to reproduce the human liver functioning as they express 99% of the same genes.

<span class="mw-page-title-main">Ulrike Protzer</span> German Virologist

Ulrike Protzer is a German virologist who has been a professor at the Chair of Virology at the Technical University of Munich (TUM) since 2007. Her primary field of study is virus-host interactions of the hepatitis B virus and her work is focused on developing new therapeutic approaches for the treatment of chronic hepatitis B infection and related secondary diseases. Since the beginning of the COVID-19 pandemic, the novel virus SARS-CoV-2 has also been one of her research areas, and she has been a prominent voice in German media on this topic.

References

  1. ↑ Mosevitskaia TV, Pavel'chuk EB, Tomilin NV (1976). "[Substrate of a UV-induced repair system providing for W-reactivation of lambda phage]". Genetika (in Russian). 12 (8): 131–8. PMID   1001892.
  2. ↑ Kunisada, T.; H. Yamagishi (November 1984). "Sequence repetition and genomic distribution of small polydisperse circular DNA purified from HeLa cells". Gene . 31 (1–3): 213–223. doi:10.1016/0378-1119(84)90212-9. PMID   6098526.
  3. ↑ Guo H.; D. Jiang; T. Zhou; A. Cuconati; T.M. Block; J.T. Guo (November 2007). "Characterization of the intracellular deproteinized relaxed circular DNA of hepatitis B virus: an intermediate of covalently closed circular DNA formation". J Virol. 81 (22): 12472–12484. doi:10.1128/JVI.01123-07. PMC   2169032 . PMID   17804499.
  4. ↑ Bourne, E.J.; Dienstag, J.L.; Lopez, V.A.; et al. (January 2007). "Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy". Journal of Viral Hepatitis. 14 (1): 56–63. doi:10.1111/j.1365-2893.2006.00775.x. PMID   17212645. S2CID   21563920.
  5. 1 2 Xia, Yuchen; Guo, Haitao (August 2020). "Hepatitis B Virus cccDNA: Formation, Regulation and Therapeutic Potential". Antiviral Research. 180: 104824. doi:10.1016/j.antiviral.2020.104824. PMC   7387223 . PMID   32450266.
  6. 1 2 3 Allweiss, Lena; Dandri, Maura (June 21, 2017). "The Role of cccDNA in HBV Maintenance". Viruses. 9 (6): 156. doi: 10.3390/v9060156 . PMC   5490831 . PMID   28635668.
  7. ↑ Kitamura, Kouichi; Que, Lusheng; Shimadu, Miyuki; Koura, Miki; Ishihara, Yuuki; Wakae, Kousho; Nakamura, Takashi; Watashi, Koichi; Wakita, Takaji; Muramatsu, Masamichi (June 21, 2018). "Flap endonuclease 1 is involved in cccDNA formation in the hepatitis B virus". PLOS Pathogens. 14 (6): e1007124. doi:10.1371/journal.ppat.1007124. PMC   6013022 . PMID   29928064.
  8. ↑ Dong, J; Ying, J; Qiu, X; Zhang, M (November 19, 2017). "Advanced Strategies for Eliminating the cccDNA of HBV". Digestive Diseases and Sciences. 63 (1): 7–15. doi:10.1007/s10620-017-4842-1. PMID   29159681. S2CID   21656087.
  9. ↑ "Heptitis B Information". Center for Disease Control. Retrieved October 6, 2020.
  10. 1 2 "Recommended Child and Adolescent Immunization Schedule for ages 18 years or younger, United States, 2020". Center for Disease Control. Retrieved October 6, 2020.
  11. 1 2 Werle-Lapostolle, Bettina; Bowden, Scott; Locarnini, Stephen; Wursthorn, Karsten; Petersen, Jorg; Lau, George; Trepo, Christian; Marcellin, Patrick; Goodman, Zachary; Delaney, William E.; Xiong, Shelly (June 2004). "Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy". Gastroenterology. 126 (7): 1750–1758. doi:10.1053/j.gastro.2004.03.018. ISSN   0016-5085. PMID   15188170.
  12. 1 2 Yang, Hung-Chih; Kao, Jia-Horng (September 2014). "Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance". Emerging Microbes & Infections. 3 (9): e64. doi:10.1038/emi.2014.64. ISSN   2222-1751. PMC   4185362 . PMID   26038757.
  13. 1 2 3 Allweiss, Lena; Dandri, Maura (2017-06-21). "The Role of cccDNA in HBV Maintenance". Viruses. 9 (6): 156. doi: 10.3390/v9060156 . ISSN   1999-4915. PMC   5490831 . PMID   28635668.
  14. ↑ Belloni, Laura; Pollicino, Teresa; Nicola, Francesca De; Guerrieri, Francesca; Raffa, Giuseppina; Fanciulli, Maurizio; Raimondo, Giovanni; Levrero, Massimo (2009-11-24). "Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function". Proceedings of the National Academy of Sciences. 106 (47): 19975–19979. Bibcode:2009PNAS..10619975B. doi: 10.1073/pnas.0908365106 . ISSN   0027-8424. PMC   2775998 . PMID   19906987.
  15. ↑ Lythgoe, Katrina A.; Lumley, Sheila F.; Pellis, Lorenzo; McKeating, Jane A.; Matthews, Philippa C. (2020). "Estimating hepatitis B virus cccDNA persistence in chronic infection". Virus Evolution. 7 (1): veaa063. doi: 10.1093/ve/veaa063 . PMC   7947180 . PMID   33732502.
  16. 1 2 Lucifora, Julie; Protzer, Ulrike (2016-04-01). "Attacking hepatitis B virus cccDNA – The holy grail to hepatitis B cure". Journal of Hepatology. Molecular Biology of Hepatitis B Virus. 64 (1, Supplement): S41–S48. doi:10.1016/j.jhep.2016.02.009. ISSN   0168-8278. PMID   27084036.
  17. ↑ Li, Feng; Cheng, Liang; Murphy, Christopher M.; Reszka-Blanco, Natalia J.; Wu, Yaxu; Chi, Liqun; Hu, Jianming; Su, Lishan (2016-11-07). "Minicircle HBV cccDNA with a Gaussia luciferase reporter for investigating HBV cccDNA biology and developing cccDNA-targeting drugs". Scientific Reports. 6 (1): 36483. Bibcode:2016NatSR...636483L. doi:10.1038/srep36483. ISSN   2045-2322. PMC   5098228 . PMID   27819342.
  18. 1 2 Gripon, Philippe; Rumin, Sylvie; Urban, Stephan; Seyec, Jacques Le; Glaise, Denise; Cannie, Isabelle; Guyomard, Claire; Lucas, Josette; Trepo, Christian; Guguen-Guillouzo, Christiane (2002-11-26). "Infection of a human hepatoma cell line by hepatitis B virus". Proceedings of the National Academy of Sciences. 99 (24): 15655–15660. Bibcode:2002PNAS...9915655G. doi: 10.1073/pnas.232137699 . ISSN   0027-8424. PMC   137772 . PMID   12432097.
  19. ↑ Gripon, Philippe; Diot, Christian; Guguen-Guillouzo, Christiane (1993-02-01). "Reproducible High Level Infection of Cultured Adult Human Hepatocytes by Hepatitis B Virus: Effect of Polyethylene Glycol on Adsorption and Penetration". Virology. 192 (2): 534–540. doi:10.1006/viro.1993.1069. ISSN   0042-6822. PMID   8421898.
  20. ↑ Guo, Haitao. "Molecular Mechanisms of HBV cccDNA Formation". Grantome. Retrieved 1 December 2020.
  21. 1 2 Long, Quanxin; Yan, Ran; Hu, Jieli; Cai, Dawei; Mitra, Bidisha; Kim, Elena S.; Marchetti, Alexander; Zhang, Hu; Wang, Soujuan; Liu, Yuanjie; Huang, Ailong (December 2017). "The role of host DNA ligases in hepadnavirus covalently closed circular DNA formation". PLOS Pathogens. 13 (12): e1006784. doi:10.1371/journal.ppat.1006784. ISSN   1553-7374. PMC   5747486 . PMID   29287110.
  22. 1 2 3 Levrero, Massimo; Pollicino, Teresa; Petersen, Jorg; Belloni, Laura; Raimondo, Giovanni; Dandri, Maura (2009-09-01). "Control of cccDNA function in hepatitis B virus infection". Journal of Hepatology. 51 (3): 581–592. doi: 10.1016/j.jhep.2009.05.022 . ISSN   0168-8278. PMID   19616338.
  23. ↑ Tuttleman, Jan S.; Pourcel, Christine; Summers, Jesse (1986-11-07). "Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells". Cell. 47 (3): 451–460. doi:10.1016/0092-8674(86)90602-1. ISSN   0092-8674. PMID   3768961. S2CID   44818698.
  24. ↑ Nguyen, David H.; Ludgate, Laurie; Hu, Jianming (2008). "Hepatitis B virus–cell interactions and pathogenesis". Journal of Cellular Physiology. 216 (2): 289–294. doi:10.1002/jcp.21416. ISSN   1097-4652. PMC   4386630 . PMID   18302164.
  25. ↑ Dandri, Maura; Lutgehetmann, Marc; Volz, Tassilo; Petersen, Jörg (May 2006). "Small Animal Model Systems for Studying Hepatitis B Virus Replication and Pathogenesis". Seminars in Liver Disease. 26 (2): 181–191. doi:10.1055/s-2006-939760. ISSN   0272-8087. PMID   16673296.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.